Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells

Nucleic Acids Research
Kristen E ClementsGeorge-Lucian Moldovan

Abstract

BRCA proteins are essential for homologous recombination (HR) DNA repair, and their germline or somatic inactivation is frequently observed in human tumors. Understanding the molecular mechanisms underlying the response of BRCA-deficient tumors to chemotherapy is paramount for developing improved personalized cancer therapies. While PARP inhibitors have been recently approved for treatment of BRCA-mutant breast and ovarian cancers, not all patients respond to this therapy, and resistance to these novel drugs remains a major clinical problem. Several mechanisms of chemoresistance in BRCA2-deficient cells have been identified. Rather than restoring normal recombination, these mechanisms result in stabilization of stalled replication forks, which can be subjected to degradation in BRCA2-mutated cells. Here, we show that the transcriptional repressor E2F7 modulates the chemosensitivity of BRCA2-deficient cells. We found that BRCA2-deficient cells are less sensitive to PARP inhibitor and cisplatin treatment after E2F7 depletion. Moreover, we show that the mechanism underlying this activity involves increased expression of RAD51, a target for E2F7-mediated transcriptional repression, which enhances both HR DNA repair, and replication...Continue Reading

Citations

Feb 5, 2019·Molecular Oncology·Nicole M ReillyAlberto Bardelli
May 24, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Emily HinchcliffRobert L Coleman
Mar 22, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sarah A Cook, Anna V Tinker
Apr 11, 2019·Frontiers in Oncology·Quan ZhouMan-Zhen Zuo
Apr 8, 2020·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Eva MorenoAlain de Bruin
Feb 26, 2021·Frontiers in Pharmacology·Lan-Ya LiYan Cheng
May 13, 2021·Nucleic Acids Research·Tanay Thakar, George-Lucian Moldovan
Jun 28, 2021·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Lingyue GaoLihui Wang
Aug 10, 2021·Environmental Science and Pollution Research International·Lina ZhouYinyan He

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

TTEST

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.